title: Projecting future drug expenditures--2006.
abstract: OBJECTIVE
  Drug expenditure trends in 2004 and 2005, projected drug expenditures for 2006, and factors likely to influence drug costs are discussed.
  
  
  CONCLUSIONS
  Various factors are likely to affect drug costs, including drug prices, drugs in development, and generic drugs. In 2004 there was a continued moderation of the increase in drug expenditures. Drug expenditures increased by 8.7% from 2003 to 2004. Through the first nine months of 2005, expenditures increased by only 8.1% compared with 2004. This moderation can be attributed to several factors, including the continued trend toward higher prescription drug cost sharing for insured consumers, growing availability of generic drugs, and lack of "blockbuster" new drugs in recent years. Drug expenditures in 2006 will likely be influenced by similar factors, with few costly new products reaching the market, increased concern over product safety slowing the diffusion of those new agents that do reach the market, and several important patent expirations, leading to slower growth in expenditures.
  
  
  CONCLUSIONS
  Forecasting and managing rising drug expenditures remains a challenge. Pharmacy managers must remain vigilant in monitoring drug costs in their health system and take a proactive role in pursuing efficient drug utilization. The dynamic health policy environment further complicates drug budgeting and must be considered, especially in integrated health systems responsible for managing inpatient, outpatient, and clinic drug costs. The comparison of health-system-specific data and trends with the national information presented in this article may provide a useful context when presenting institutional drug costs to senior management.
authors.affiliation: Pharmaceutical Department, St. Jude Children's Research Hospital, Memphis, TN, USA.
authors.forename: James M
authors.initials: JM
authors.lastname: Hoffman
authors.forename: Nilay D
authors.initials: ND
authors.lastname: Shah
authors.forename: Lee C
authors.initials: LC
authors.lastname: Vermeulen
authors.forename: Glen T
authors.initials: GT
authors.lastname: Schumock
authors.forename: Penny
authors.initials: P
authors.lastname: Grim
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hunkler
authors.forename: Karrie M
authors.initials: KM
authors.lastname: Hontz
mesh_terms: D035843:Biomedical Research / Q000191:economics / Q000639:trends; D002017:Budgets / Q000639:trends*; D004059:Diffusion of Innovation; D017277:Drug Approval; D016527:Drug Costs / Q000639:trends*; D016568:Drugs, Generic / Q000191:economics; D006801:Humans; D006278:Medicare / Q000191:economics; D010607:Pharmacy Service, Hospital / Q000191:economics* / Q000639:trends*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016568:Drugs, Generic